key: cord-0265583-cj5sy0zm
authors: Leung, N. H. L.; Cheng, S. M. S.; Martin-Sanchez, M.; Au, N. Y. M.; Ng, Y. Y.; Luk, L. L. H.; Chan, K. C. K.; Li, J. K. C.; Leung, Y. W. Y.; Tsang, L. C. H.; Chaothai, S.; Kwan, K. K. H.; Ip, D. K. M.; Poon, L. L. M.; Leung, G. M.; Peiris, M.; Cowling, B. J.
title: BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults who previously received two doses of inactivated vaccine
date: 2022-01-21
journal: nan
DOI: 10.1101/2022.01.20.22269586
sha: 04cbdd87340d926c2558c524c043d09f00235161
doc_id: 265583
cord_uid: cj5sy0zm

Limited data exist on antibody responses to mixed vaccination strategies involving inactivated COVID-19 vaccines, particularly in the context of emerging variants. We conducted an open label trial and administered a third vaccine dose of an mRNA vaccine (BNT162b2, BioNTech/Fosun Pharma) in adults aged [≥]30 years who had previously received two doses of an inactivated COVID-19 vaccine. We collected blood samples prior to administering the third dose and 28 days later, and tested for antibodies to the ancestral virus using a binding assay (ELISA), a surrogate virus neutralization test (sVNT) and a live virus plaque reduction neutralization test (PRNT), and to the Omicron variant using PRNT. A third dose of BNT162b2 substantially increased antibody titers on each assay. Mean ELISA levels increased from an optical density (OD) of 0.3 to 2.1 (p<0.01), and mean sVNT levels increased from an inhibition of 17% to 96% (p<0.01). In a random subset of 20 participants, the geometric mean PRNT50 titers rose very substantially by at least 27 fold from Day 0 to Day 28 against the ancestral virus (p<0.01) and rose by at least 14 fold against the Omicron variant (p<0.01). In daily monitoring, post-vaccination reactions subsided within 7 days for over 99% of participants. In conclusion, a third dose of COVID-19 vaccination with an mRNA vaccine substantially improved antibody levels against the ancestral virus and against the Omicron variant with well-tolerated safety profile, in adults who had received two doses of inactivated vaccine 6 months earlier.

Limited data exist on antibody responses to mixed vaccination strategies involving inactivated 23 COVID-19 vaccines, particularly in the context of emerging variants. We conducted an open 24 label trial and administered a third vaccine dose of an mRNA vaccine (BNT162b2, 25 BioNTech/Fosun Pharma) in adults aged ≥30 years who had previously received two doses of an 26 inactivated COVID-19 vaccine. We collected blood samples prior to administering the third dose 27 and 28 days later, and tested for antibodies to the ancestral virus using a binding assay (ELISA), The emergence of variants of concern (VOCs), such as the Omicron and delta variants, and 55 observed decrease in vaccine-induced immune responses within a few months after the second 56 vaccine dose have resulted in the administration of third doses in some locations (4). Zeng et al. 57 reported a placebo-controlled, randomized, double-blind phase II trial of three doses of 58 CoronaVac at different vaccination intervals and dosages in adults aged 18-59 years, and another 59 similar trial in older adults aged ≥60 years but with different dosages only were conducted in 60 China (5). In the 3μg group (the same dosage as used in the population), neutralizing antibody 61 titers against the ancestral virus declined to below the seropositivity cut-off 5-8 months after the 62 second dose in both younger and older adults, but administering a third dose 8 months after 63 second dose increased the GMT titer to 143 and 159 respectively; in addition, only grade 1 or 2 64 solicited local and systemic adverse reactions were reported within 28 days after receiving the 65 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 third dose with incidence not higher than each previous dose (5). Some studies reported 66 immunogenicity of heterologous third dose COVID-19 vaccination approximately 1-3 months 67 shortly after recipient of two-dose inactivated vaccine, where all three doses were originally 68 designed to be against the ancestral virus (6, 7). Pérez-Then et al. analysed plasma samples from 69 adults collected 28 days after a BNT162b2 third dose was administered at least 4 weeks after 70 receiving the two-dose CoronaVac, who may or may not have been previously infected with 71 SARS-CoV-2 (6). They showed that a third dose BNT162b2 vaccination gave rise to a 1.4-fold 72 increase in neutralizing antibodies (PRNT50) against the Omicron variant when compared to two-73 dose mRNA vaccine (BNT162b2 or mRNA-1273), but was less by 6.3-fold and 2.7-fold when 74 compared to the boost against ancestral virus and the Delta variant respectively. They also 75 reported there was no neutralizing antibodies to Omicron about 3-4 months after the two-dose 76 Coronavac vaccination and prior to the third dose BNT162b2 vaccination. Another study by 77 Intapiboon et al. randomized healthy adults aged 18-60 years who previously received the two-78 dose CoronaVac about 2.5 months earlier to either administration of a full-dose intramuscularly, 79 half-dose intramuscularly or one-fifth-dose intradermally of a booster dose BNT162b2, and 80 showed a median neutralizing antibody titer (PRNT50) of 563 against the delta variant 14 days 81 after booster vaccination (7). However, no published study has examined the use of an mRNA 82 vaccine administered as a third dose approximately 6 months after receipt of two doses of an 83 inactivated vaccine, a vaccination program strategy being urgently considered around the world 84 for populations who previously received inactivated vaccines especially in the context of 85 emerging variants such as the Omicron variant. We therefore conducted a trial of the 86 immunogenicity and reactogenicity to a third dose of an mRNA vaccine (BNT162b2) in adults 87 who had previously received two doses of inactivated COVID-19 vaccination.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. vaccination at least 90 days ago were eligible to enrol into our study (Fig. S1 ), 75% of the study 101 participants reported receiving the second dose typically around 6-7 months earlier (Table 1) .

Characteristics of the 314 participants at enrolment are shown in Table 1 Omicron variant for Day 0 and Day 28 available for a random subset of 20 of these participants.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Figure 1 shows that a third dose of BNT substantially increased antibody titers measured by the 112 various assays. Mean ELISA levels increased from a OD of 0.3 to 2.1 (p<0.01), and mean sVNT 113 levels increased from an inhibition of 17% to 96% (p<0.01). In the subset of 20 participants for 114 whom PRNT titers against the ancestral strain were available, the geometric mean PRNT50 titer 115 against the ancestral strain at Day 0 was 16. We could not estimate the GMT at Day 28 because 116 18/20 (90%) samples were positive at the highest dilution of 1:320, and we noted that a GMT 117 ≥320 would correspond to a mean-fold titer rise of ≥27 from Day 0 to Day 28 (p<0.01). The 118 geometric mean PRNT90 titer against the ancestral strain at Day 0 was 6. We could not estimate 119 the GMT at Day 28 because 12/20 samples were positive at the highest dilution of 1:320, and we 120 noted that a GMT ≥320 would correspond to a mean-fold titer rise of ≥46 in PRNT90 titers from 121 Day 0 to Day 28 (p<0.01). We also measured antibody titers by PRNT against the Omicron (Table S1 ). Among the solicited systemic reactions reported, the most common were headache 138 (24%), feverish (23%), myalgia (18%), fatigue (18%), drowsiness (17%) and malaise (10%) 139 (Table S1 ). For those who reported fever ≥ 38.0ºC, the median measured highest body 140 temperature within 7 days after vaccination was 38.3ºC ). These symptoms 141 usually subsided within 7 days after third dose BNT162b2 vaccination (Fig. 2) . Reports of other 142 flu-like symptoms (e.g., cough, runny nose), gastrointestinal symptoms (e.g., nausea and 143 diarrhoea) or systematic symptoms (e.g., skin rash, joint pain and abnormal heart beat) were 144 infrequent (<10%) ( Table S1 ). Among the participants, 6 (2%) reported having sought medical 145 consultation within one month of the third dose but none were hospitalized. Among these 6 146 participants, 4 reported seeking medical consultation possibly for discomfort associated with 147 vaccination within the week after vaccination, and the remaining two participants sought medical 148 consultation due to back pain or stress outside the 7-day window. showed that a third dose of inactivated vaccine given to healthy young adults at 8 months after 155 the second dose of the same vaccine was able to boost neutralizing antibodies against the 156 ancestral strain by about 21 fold (5). Here, we show that a third dose of mRNA vaccine (BNT162b2) after two doses of inactivated virus vaccine (mostly CoronaVac), all originally 158 formulated against the ancestral virus, was able to boost PRNT50 titers against the ancestral strain 159 by a factor of at least 27 fold, a substantial improvement over a third dose of inactivated vaccine. 160 We also show that a third dose of BNT162b2 conferred moderate rises in PRNT50 titers against 161 the Omicron variant by a factor of at least 14 fold. While there is still a lack of consensus on the 162 antibody threshold for protection (8-11), the PRNT50 titers against Omicron at Day 28 in our 163 study are higher than the PRNT50 titers against ancestral virus after two doses of CoronaVac 164 where the geometric mean PRNT50 titer was estimated to be 27 (2). Given that two doses of 165 inactivated vaccine were estimated to provide at least 50% protection against infection with the 166 ancestral virus (12-14), we would expect the antibody levels against Omicron estimated in our 167 study to correspond to somewhat more than 50% effectiveness in protection against Omicron. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269586 doi: medRxiv preprint which targets to vaccinate populations every 6 months is a feasible alternative to annual (re-181 )vaccination and has been considered for influenza vaccination amid a mismatched vaccine (15), 182 and could be a more efficient and realistic strategy than a mass vaccination program with shorter 183 intervals. Separately, earlier studies suggested that reactogenicity for two doses of mRNA 184 vaccines was greater than for two doses of inactivated vaccines (16). Our study shows that third Omicron strain up to a dilution of 1:320. However, more than half of our study participants were 203 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269586 doi: medRxiv preprint positive for antibodies to the ancestral strain at this dilution indicating antibody titers ≥320, and 204 we were therefore not able to determine exactly the GMT against ancestral strain after third dose 205 mRNA vaccination but only confirm that it was ≥320. Similarly, Day 0 samples were typically 206 negative even at the starting dilution of 1:10, limiting our assessment of pre-vaccination GMTs.

Nevertheless, we were able to conclude that third dose of mRNA vaccination would provide 208 substantial benefits against both ancestral and Omicron strains by comparing the lower bound of 209 the antibody boosting with the antibody level boosted after two doses of inactivated vaccination.

Our results on immunogenicity may be subjected to selection bias including volunteer bias, since 211 in Hong Kong older adults are more inclined to receive the inactivated vaccines and younger 212 adults to mRNA vaccines (20). Indeed, while our study aimed to enrol adults aged ≥ 30 years, 213 over 75% of study participants were ≥ 47 years old. Individuals who have received a self-funded 214 commercial antibody test before enrolment with identified low antibody level might also have 215 been more inclined to join studies on third dose vaccination, although only 6% of our study 216 participants reported this as one of the major reasons for joining our study (data not shown). CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022.

This was an open-label single-arm clinical trial with allocation concealment, to measure the 226 antibody responses and reactogenicity of an mRNA vaccine (BNT162b2) given as a third CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10. 1101 /2022 were provided with a free tympanic thermometer at enrolment, and a gift voucher of HK$100 246 (US$13) at the blood draws on Days 28, 182 and 365. We also excluded potential participants with diagnosed medical conditions related to their 255 immune system, use of medication that impairs immune system in the last 6 months except 256 topical steroids or short-term oral steroids (course lasting ≤14 days), those who had used 257 immunoglobulins and/or any blood products within 90 days prior to enrolment, and any females 258 who were pregnant or intending to become pregnant in the coming 3 months.

We collected 20 ml clotted blood specimens at the day of enrolment and vaccination (day 0) and 261 again after 28 days, with additional blood draws planned after 182 and 365 days, to assess serum 262 neutralizing antibody responses. After vaccination, participants were observed for 30 minutes to 263 record any immediate events. We then asked participants to report information on immediate and 264 delayed local or systematic events, as well as the body temperature measured using the tympanic 265 thermometer that we provided to them after vaccination as incentive, daily within the first 7 days 266 after receipt of BNT162N2 using an online e-diary. If the participant was still reporting any 267 reaction on Day 7, additional daily monitoring continued for up to three additional weeks until 268 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. Sample size justification 296 We aimed to enroll 300 participants into our study. While our primary outcome is the GMT at 297 day 28 and not a comparison, we also compared the mean fold rise in GMT at day 28 versus day 298 0 (the "strength" of the boost). Based on our preliminary data, assuming a GMT of 27 at Day 0 299 with a standard deviation of 0.85, a sample size of 300 individuals would provide 80% power to 300 detect a mean fold rise of 1.1 or greater at the 5% significance level.

Blood samples were delivered to our study laboratory at the University of Hong Kong as soon as 304 possible, with the optimal delivery time within 24 hours after collection for further processing. 305 Sera were extracted from the clotted blood within 48 hours after collection, divided into 2-4 306 aliquots, and stored at -80°C until subsequent serologic testing. We tested sera heat inactivated at 307 56 o C for 30 minutes with three assays, our in-house enzyme-linked immunosorbent assay 308 (ELISA) for the receptor binding domain (RBD) of the spike protein, a surrogate virus 309 neutralisation test (sVNT), and a plaque reduction neutralisation test (PRNT) as previously 310 described (23-25). ELISA and sVNT were performed in all paired Day 0 and Day 28 sera 311 available as described in the Results, and PRNT against ancestral SARS-CoV-2 virus and the 312 Omicron variant were performed in paired Day 0 and Day 28 sera from 20 participants randomly 313 selected from these participants using statistical program. PRNT assays were carried out using 314 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. 328 We assessed the GMT of SARS-CoV-2 neutralizing antibodies and the mean concentrations of 329 SARS-CoV-2 Spike RBD IgG (proxy by OD450) and surrogate virus neutralization percentages 330 at Day 28. PRNT titers were interval censored, e.g. a sample that was able to neutralise virus at a 331 1:20 dilution but not at a 1:40 dilution was reported as 20 but indicating the titer was ≥20 and 332 <40. We therefore used midpoints on the log scale for measured titers. For example a measured 333 titer of ≥20 to <40 was imputed as 28. We imputed titers <10 with the value 5 and titers ≥320 334 with the value 452 for estimation of GMTs. We compared ratios of baseline antibody levels to CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269586 doi: medRxiv preprint by Spearman's rank correlation coefficient. Reactogenicity endpoints were described as CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10. 1101 /2022 Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 plaque reduction neutralization test (PRNT) against ancestral strain with endpoints at (C) 50% 505 (PRNT50) or (D) 90% (PRNT90) with X indicating the median level on each assay because GMTs 506 could not be estimated. Live virus plaque reduction neutralization test (PRNT) against Omicron 507 variant with endpoints at (E) 50% (PRNT50) or (F) 90% (PRNT90) with X indicating the GMTs.

PRNT titers are measured based on two-fold dilutions and plotted here within an interval, or <10 509 (plotted on x-axis) or ≥320 (plotted above 320). 510 511 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. are measured based on two-fold dilutions and plotted here within an interval, or <10 (plotted on 541 axis) or ≥320 (plotted above 320). r: Spearman's rank correlation coefficient.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10. 1101 /2022 (5) 9 (3) Chest discomfort 13 (4) 9 (3) Diarrhoea 13 (4) 4 (1) Abdominal distention 11 (4) 6 (2) Palpitations 11 (4) 5 (2) Insomnia 11 (4) 5 (2) Phlegm 10 (3) 5 (2) Nausea 9 (3) 5 (2) Cough 8 (3) 4 (1) Abdominal pain 7 (2) 4 (1) Constipation 6 (2) 4 (1) Body itching 5 (2) 2 (1)

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10. 1101 /2022 Flushing of the face 4 (1) 3 (1) Skin rash 3 (1) 1 (0) Chest pain 3 (1) 0 (0) Enlarged lymph nodes 3 (1) 0 (0) Face swelling 2 (1) 0 (0) Arm or leg swelling 1 (0) 1 (0) Muscle spasms 1 (0) 1 (0) Confusion 1 (0) 1 (0) Dyspnea 1 (0) 0 (0) Nosebleeds 0 (0) 0 (0) Ageusia 0 (0) 0 (0) Anosmia 0 (0) 0 (0) Conjunctivitis 0 (0) 0 (0) Vomiting 0 (0) 0 (0) Facial drooping/ weakness 0 (0) 0 (0) Loss of consciousness 0 (0) 0 (0) Seizure 0 (0) 0 (0) 550 551 552 553 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10. 1101 /2022 

Research 437 electronic data capture (REDCap)--a metadata-driven methodology and workflow 438 process for providing translational research informatics support

The REDCap consortium: Building an 442 international community of software platform partners

Serological assays for severe 447 acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human

 461 We gratefully acknowledge colleagues including Eileen Yu, Teresa So and Zacary Chai for 462 technical support in preparing and conducting this study; Anson Ho for setting up the database; 463 Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung